CRP and viral infectious disease: The National Institute for Health and Care Excellence (NICE) guidelines has recommended Tocilizumab treatment in patients with COVID-19 receiving Oxygen treatment with a CRP of ≥ 75 mg/L provided there is no evidence of bacterial or other viral infections that could be worsened by immunosuppression [27].